Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs Trastuzumab + Pertuzumab in HER2+ Early Breast Cancer with Postoperative ctDNA Positivity
NCT07856303Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Aug 2032
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07856303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07856303.